Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...
AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you ...
AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Morgan Stanley lowered the firm’s price target on AbbVie (ABBV) to $224 from $231 and keeps an Overweight rating on the shares following ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...
Hosted on MSN14h
AbbVie’s stock plummets over 12% after schizophrenia drug flops in Phase II trialsAbbVie’s stock price fell over 12% after emraclidine, an investigational anti-psychotic being evaluated for the treatment of ...
Stocktwits on MSN1d
AbbVie Stock Declines After Schizophrenia Drug Trials Miss Mark, But Retail Stays StoicShares of pharma major AbbVie Inc ($ABBV) tumbled over 12% on Monday after the company disclosed that its Schizophrenia drug ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
However, arguably the next best thing is for a company to belong to the elite group known as Dividend Kings. To qualify, a ...
On Tuesday, AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $201.68 which represents a slight increase of $1.21 or 0.60% from the prior close of $200.47. The stock opened at $200.49 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback